Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses

Journal of Clinical Microbiology

Volumn 41, Issue 7, 2003, Pages 2827-2834

  Studentsov, Yevgeniy Y ^a   Ho, Gloria Y F ^a   Marks, Morgan A ^a   Bierman, Robert ^b   Burk, Robert D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; POLYMER; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DNA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL TRACT INFECTION; HUMAN; HUMAN TISSUE; INDEPENDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OPTICAL DENSITY; PAPANICOLAOU TEST; PARENT; PREVALENCE; PRIORITY JOURNAL; SEROLOGY; SEROPREVALENCE; SERUM; SEXUAL INTERCOURSE; SEXUALITY; UTERINE CERVIX CYTOLOGY; VAGINA; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS PARTICLE; VIRUS STRAIN; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VIRAL LOAD; VIRION;

DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0038152717     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.7.2827-2834.2003     Document Type: Article

References (41)

1. Bauer, H. M., M. S. YiTing, C. E. Greer, J. C. Chambers, C. J. Tashiro, J. Chimera, A. Reingoid, and M. M. Manos. 1991. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265:472-477.
2. Bontkes, H. J., T. D. de Gruijl, J. M. M. Walboomers, J. T. Schiller, J. Dilner, T. J. M. Helmerhorst, R. H. M. Verheijen, R. J. Scheper, and C. J. L. M. Meijer. 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systematic but not local IgA responses correlate with clearance of HPV-16. J. Gen. Virol. 80:409-417.
3. Bosch, F. X., M. M. Manos, N. Munoz, M. Sherman, A. Jansen, J. Peto, M. Schiffman, V. Moreno, R. Kurman, K. Shah, and I. S. Group. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
4. Burk, R. D., G. Y. F. Ho, L. Beardsley, M. Lempa, M. Peters, and R. Bierman. 1996. Sexual behavior and partner selection are the predominant risk factors for genital HPV infection in young women. J. Infect. Dis. 174:679-689.
5. Burk, R. D., A. S. Kadish, S. Calderin, and S. L. Romney. 1986. Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: correlation with biopsy results and Papanicolaou smear. Am. J. Obstet. Gynecol. 15:982-989.
6. Carter, J. J., L A. Koutsky, G. C. Wipf, N. D. Christensen, S.-K. Lee, J. Kuypers, N. Kiviat, and D. A. Galloway. 1996. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis. 174:927-936.
7. Carter, J. J., G. C. Wipf, M. E. Hagensee, B. McKnight, L. A. Habel, S. K. Lee, J. Kuypers, N. Kiviat, J. R. Daling, L. A. Koutsky, H. D. Watts, K. K. Holmes, and D. A. Galloway. 1995. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J. Infect. Dis. 172:11-18.
8. Christensen, N. D., R. Hopfl, S. L. DiAngelo, N. M. Cladel, S. D. Patrick, P. A. Welsh, L. R. Budgeon, C. A. Reed, and J. W. Kreider. 1994. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titers of neutralizing antibodies. J. Gen. Virol. 75:2271-2276.
9. Christensen, N. D., J. W. Kreider, K. V. Shah, and R. F. Rando. 1992. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J. Gen. Virol. 73:1261-1267.
10. de Villiers, E.-M. 2001. Taxonomic classification of papillomavirures. Papillomavirus Rep. 12:57-63.
11. Dillner, J., I. Kallings, C. Brihmer, B. Sikstrom, P. Koskela, M. Lehtinen, J. T. Schiller, M. Sapp, and P. A. Mardh. 1996. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J. Infect. Dis. 173:1394-1398.
12. Duggan, M. A., S. E. McGrqor, G. C. Stuart, S. Morris, V. Chang-Poon, A. Schepansky, and L. Honore. 1998. The natural history of CIN I lesions. Eur. J. Gynaecol. Oncol. 19:338-344.
13. Evander, M., K. Edlund, A. Gustafsson, M. Jonsson, R. Karlsson, E. Rylander, and G. Wadell. 1995. Human papillomavirus infection is transient in young women: a population-based cohort study. J. Infect. Dis. 171:1026-1030.
14. Galloway, D. 1992. Serological assays for the detection of HPV antibodies. IARC Sci. Publ. 119:147-161.
15. Giroglou, T., M. Sapp, C. Lane, C. Fligge, N. D. Christensen, R. E. Strreck, and R. C. Rose. 2001. Immunological analyses of human papillomavirus capsids. Vaccine 19:1783-1793.
16. Hagensee, M. E., N. Yaegashi, and D. A. Galloway. 1993. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67:315-322.
17. Ho, G. Y. F., R. Bierman, L. Beardsley, C. J. Chang, and R. D. Burk. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:423-428.
18. Ho, G. Y. F., R. D. Burk, S. Klein, A. S. Kadish, C. J. Chang, P. Palan, J. Basu, R. Tachezy, R. Lewis, and S. Romney. 1995. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87:1365-1371.
19. Ho, G. Y. F., Y. Studentsov, C. B. Hall, R. Bierman, L. Beardsley, M. Lempa, and R. D. Burk. 2002. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J. Infect. Dis. 186:737-742.
20. Karlsson, R., M. Jonsson, K. Edlund, M. Evander, A. Gustavsson, E. Boden, E. Rylander, and G. Wadell. 1995. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex. Transm. Dis. 22:119-127.
21. Kirnbauer, R., N. L. Hubbert, C. M. Wheeler, T. M. Becker, D. R. Lowy, and J. T. Schiller. 1994. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. Natl. Cancer Inst. 86:494-499.
22. Kirnbauer, R., J. Taub, H. Greenstone, R. Roden, M. Durst, L. Gissmann, D. R. Lowy, and J. T. Schiller. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:6929-6936.
23. Kjellberg, L., Z. Wang, F. Wilklund, K., Ddlund, T. Angstrom, P. Lenner, I. Sjoberg, G. Hallmans, K. L. Wallin, M. Sapp, J. Schiller, G. Wadell, C. G. Mahick, and J. Dillner. 1999. Sexual behavior and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J. Gen. Virol. 80:391-398.
24. Koutsky, L. A., K. K. Holmes, C. W. Critchlow, C. E. Stevens, J. Paavonen, A. M. Beckmann, T. A. DeRouen, D. A. Galloway, D. Vernon, and N. B. Kiviat. 1992. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327:1272-1278.
25. Moscicki, A.-B., J. Palefsky, J. Gonzales, and G. K. Schoolnik. 1990. Human papillomavirus infection in sexually active adolescent females: prevalence and risk factors. Pediatr. Res. 28:507-513.
26. Moscicki, A.-B., S. Shiboski, J. Broering, K. Powell, L. Clayton, N. Jay, T. M. Darragh, R. Brescia, S. Kanowitz, S. B. Miller, J. Stone, E. Hanson, and J. Palefsky. 1998. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J. Pediatr. 132:277-284.
27. National Cancer Institute and Workshop. 1989. The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses. JAMA 262:931-934.
28. Palefsky, J. M., H. Minkoff, L. A. Kalish, A. Levine, H. S. Sacks, P. Garcia, M. Young, S. Melnick, P. Miotti, and R. Burk. 1999. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J. Natl. Cancer Inst. 91:226-236.
29. Petry, K. U., D. Scheffel, U. Bode, T. Gabrysiak, H. Kochel, E. Kupsch, M. Glaubitz, S. Niesert, H. Kuhnle, and I. Schedel. 1994. Cellular immonodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer 67:836-840.
30. Remmink, A. J., J. M. Walboomers, T. J. Helmerhorst, F. J. Voorhorst, L. Rozendaal, E. K. Risse, C. J. Meijer, and P. Kenemans. 1995. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer 61:306-311.
31. Roden, R. B., H. L. Greenstone, R. Kirnbauer, F. P. Booy, J. Jessie, D. R. Lowy, and J. T. Schiller. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:5875-5883.
32. Roden, R. B., N. L. Hubbert, R. Kirnbauer, N. D. Christensen, D. R. Lowy, and J. T. Schiller. 1996. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70:3298-3301.
33. Rose, R. C., W. Bonnez, R. C. Reichman, and R. L. Garcea. 1993. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles. J. Virol. 67:1936-1944.
34. Studentsov, Y. Y., M. Schiffman, H. D. Strickler, G. Y. F. Ho, J. Schiller, R. Herrero, and R. D. Burk. 2002. Enchanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J. Clin. Microbiol. 40:1755-2760.
35. Touze, A., S. de Sanjose, P. Coursaget, M. R. Almirall, V. Palacio, C. J. L. M. Meijer, J. Kornegay, and F. X. Bosch. 2001. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women with the general population and in prostitutes. J. Clin. Microbiol. 39:4344-4348.
36. Viscidi, R. P., K. L. Kotloff, B. Clayman, K. Russ, S. Shapiro, and K. V. Shah. 1997. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol. 4:122-126.
37. Wang, Z., N. Christensen, J. Schiller, and J. Dillner. 1997. A monoclonal antibody against intact human papillomavirus type 16 blocks the serological reactivity of most human sera. J. Gen. Virol. 78:2209-2215.
38. Wang, Z. H., L. Kjellberg, H. Abdalla, F. Wiklund, C. Eklund, P. Knekt, M. Lehtinen, I. Kallings, P. Lenner, G. Hallmans, C. G. Mahlck, G. Wadell, J. Schiller, and J. Dillner. 2000. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J. Infect. Dis. 181:456-462.
39. Wideroff, L., M. Schiffman, P. Haderer, A. Armstrong, C. E. Greer, M. M. Manos, R. D. Burk, D. R. Scott, M. E. Sherman, J. T. Schiller, R. N. Hoover, R. E. Tarone, and R. Kirnbauer. 1999. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J. Infect. Dis. 180:1424-1428.
40. Zhou, J., X. Y. Sun, D. J. Stenzel, and I. H. Frazer. 1991. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251-257.
41. Zweig, M. H., and G. Campbell. 1993. Receiver-operating characteristics plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39:561-577.